Information Provided By:
Fly News Breaks for February 26, 2020
Feb 26, 2020 | 08:53 EDT
Bernstein analyst Aaron Gal upgraded Regeneron (REGN) to Outperform from Market Perform with a $500 price target. The analyst has been cautious around Regeneron, arguing that while near-term earning upside is there, the long-term outlook is limited by competitive pressures on Eylea and Dupixent. However, he believes the news of vasculitis cases with Novartis' (NVS) Beovu changes the balance. His discussions with practices suggest that they will narrow the new product's use and its outlook may be hampered for some time. Further, other new products may be slower to adopt, at least initially, he adds.
News For REGN;NVS From the Last 2 Days
Apr 12, 2021 | 09:28 EDT
Benchmark analyst Aydin Huseynov expects full FDA approval of Regeneron's (REGN) REGEN-COV could be coming within weeks, possibly in both 2.4g and 1.2g doses, citing the 70% reduction in risk of hospitalization or death in a 4,600-patient REGEN-COV randomized placebo-controlled trial in non-hospitalized COVID-19 patients as well as what he sees as "an apparent preference" for Regeneron's cocktail over Eli Lilly's (LLY). Huseynov has a Buy rating and $590 price target on Regeneron shares.